Roche has revealed that its humanised monoclonal antibody Ocrevus (ocrelizumab) received a positive recommendation from the Committee for Medical Products for Human Use (CHMP) in the treatment of active relapsing forms of multiple sclerosis.

Bron: Pharmafile | lees verder..